Ovarian cancer is one of the most common gynecological malignancies. The 5-year survival rate of ovarian cancer is only 50%, which is considered to be the most lethal gynecologic malignant tumor.The high mortality of ovarian cancer patients can be attributed to chemotherapy resistance, extensive intraperitoneal metastasis and other factors.Tumor antigens are expressed on the surface of tumor cells and represent potential drug targets.One of the antigens is tumor associated nectin-4, which is a member of the immune globulin superfamily.This review highlights the role of nectin-4 as a therapeutic target for ovarian cancer, and discusses the relevant research data, which is an effective new direction in the treatment of ovarian cancer.Although there are still some challenges, targeted therapy is still a promising treatment for ovarian cancer.
References
[1]
Timmermans, M., Sonke, G.S., van de Vijver, K.K., van der Aa, M.A. and Kruitwagen, R. (2018) No Improvement in Long-Term Survival for Epithelial Ovarian Cancer Patients: A Population-Based Study between 1989 and 2014 in the Netherlands. European Journal of Cancer, 88, 31-37. https://doi.org/10.1016/j.ejca.2017.10.030
[2]
Brancati, F., Fortugno, P., Bottillo, I., Lopez, M., Josselin, E., Boudghene-Stambouli, O., Agolini, E., Bernardini, L., Bellacchio, E., Iannicelli, M., et al. (2010) Mutations in PVRL4, Encoding Cell Adhesion Molecule Nectin-4, Cause Ectodermal Dysplasia-Syndactyly Syndrome. The American Journal of Human Genetics, 87, 265-273. https://doi.org/10.1016/j.ajhg.2010.07.003
[3]
DeRycke, M.S., Pambuccian, S.E., Gilks, C.B., Kalloger, S.E., Ghidouche, A., Lopez, M., Bliss, R.L., Geller, M.A., Argenta, P.A., Harrington, K.M., et al. (2010) Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum: Potential Role as a Serum Biomarker. American Journal of Clinical Pathology, 134, 835-845. https://doi.org/10.1309/AJCPGXK0FR4MHIHB
[4]
Buchanan, P.C., Boylan, K.L.M., Walcheck, B., Heinze, R., Geller, M.A., Argenta, P.A. and Skubitz, A.P.N. (2017) Ectodomain Shedding of the Cell Adhesion Molecule Nectin-4 in Ovarian Cancer Is Mediated by ADAM10 and ADAM17. Journal of Biological Chemistry, 292, 6339-6351. https://doi.org/10.1074/jbc.M116.746859
[5]
Takano, A., et al. (2009) Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer. Cancer Research, 69, 6694-6703. https://doi.org/10.1158/0008-5472.CAN-09-0016
[6]
Zhang, Y., et al. (2016) A Novel PI3K/AKT Signaling Axis Mediates Nectin-4-Induced Gallbladder Cancer Cell Proliferation, Metastasis and Tumor Growth. Cancer Letters, 375, 179-189. https://doi.org/10.1016/j.canlet.2016.02.049
[7]
Pavlova, N.N., et al. (2013) A Role for PVRL4-Driven Cell-Cell Interactions in Tumorigenesis. eLife, 2, e00358. https://doi.org/10.7554/eLife.00358
[8]
Siddharth, S., et al. (2017) Nectin-4 Is a Breast Cancer Stem Cell Marker That Induces WNT/beta-Catenin Signaling via Pi3k/Akt Axis. The International Journal of Biochemistry & Cell Biology, 89, 85-94. https://doi.org/10.1016/j.biocel.2017.06.007
[9]
Rabet, M., et al. (2017) Nectin-4: A New Prognostic Biomarker for Efficient Therapeutic Targeting of Primary and Metastatic Triple-Negative Breast Cancer. Annals of Oncology, 28, 769-776. https://doi.org/10.1093/annonc/mdw678
[10]
Nishiwada, S., et al. (2015) Nectin-4 Expression Contributes to Tumor Proliferation, Angiogenesis and Patient Prognosis in Human Pancreatic Cancer. Journal of Experimental & Clinical Cancer Research, 34, Article No. 30. https://doi.org/10.1186/s13046-015-0144-7
[11]
Ma, J., et al. (2016) Expression and Clinical Significance of Nectin-4 in Hepatocellular Carcinoma. OncoTargets and Therapy, 9, 183-190. https://doi.org/10.2147/OTT.S96999
[12]
Deng, H., Shi, H., Chen, L., Zhou, Y. and Jiang, J. (2019) Over-Expression of Nectin-4 Promotes Progression of Esophageal Cancer and Correlates with Poor Prognosis of the Patients. Cancer Cell International, 19, Article No. 106. https://doi.org/10.1186/s12935-019-0824-z
[13]
Teutsch, S.M., et al. (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genetics in Medicine, 11, 3-14. https://doi.org/10.1097/GIM.0b013e318184137c
[14]
Febbo, P.G., et al. (2011) NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network, 9, S1-S32. https://doi.org/10.6004/jnccn.2011.0137
[15]
Challita-Eid, P.M., et al. (2016) Enfortumab Vedotin Antibodydrug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Research, 76, 3003-3013. https://doi.org/10.1158/0008-5472.CAN-15-1313
[16]
Birrer, M.J., Moore, K.N., Betella, I. and Bates, R.C. (2019) Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Journal of the National Cancer Institute, 111, 538-549. https://doi.org/10.1093/jnci/djz035
[17]
Lambert, J.M. and Berkenblit, A. (2018) Antibody-Drug Conjugates for Cancer Treatment. Annual Review of Medicine, 69, 191-207. https://doi.org/10.1146/annurev-med-061516-121357
[18]
Boylan, K.L.M., Buchanan, P.C., Manion, R.D., Shukla, D.M., Braumberger, K., Bruggemeyer, C. and Skubitz, A.P.N. (2017) The Expression of Nectin-4 on the Surface of Ovarian Cancer Cells Alters Their Ability to Adhere, Migrate, Aggregate, and Proliferate. Oncotarget, 8, 9717-9738. https://doi.org/10.18632/oncotarget.14206
[19]
Rosso, M., Majem, B., Devis, L., Lapyckyj, L., Besso, M.J., Llaurado, M., Abascal, M.F., Matos, M.L., Lanau, L., Castellvi, J., et al. (2017) E-cadherin: A Determinant Molecule Associated with Ovarian Cancer Progression, Dissemination and Aggressiveness. PLOS ONE, 12, e0184439. https://doi.org/10.1371/journal.pone.0184439
[20]
Usui, A., Ko, S.Y., Barengo, N. and Naora, H. (2014) P-cadherin Promotes Ovarian Cancer Dissemination through Tumor Cell Aggregation and Tumor-Peritoneum Interactions. MCR, 12, 504-513. https://doi.org/10.1158/1541-7786.MCR-13-0489
[21]
Yoshida, Y., Kurokawa, T., Nishikawa, Y., Orisa, M., Kleinman, H.K. and Kotsuji, F. (2008) Laminin-1-Derived Scrambled Peptide AG73T Disaggregates Laminin-1-Induced Ovarian Cancer Cell Spheroids and Improves the Efficacy of Cisplatin. International Journal of Oncology, 32, 673-681. https://doi.org/10.3892/ijo.32.3.673
[22]
Teo, M.Y. and Rosenberg, J.E. (2018) EMA and FDA Prune the Checkpoint Inhibitor Treatment Landscape. Nature Reviews Urology, 15, 596-597. https://doi.org/10.1038/s41585-018-0074-1
[23]
Diamantis, N. and Banerji, U. (2016) Antibody-Drug Conjugates—An Emerging Class of Cancer Treatment. British Journal of Cancer, 114, 362-367. https://doi.org/10.1038/bjc.2015.435
[24]
Thomas, A., Teicher, B.A. and Hassan, R.T. (2016) Antibody-Drug Conjugates for Cancer Therapy. The Lancet Oncology, 17, E254-E262. https://doi.org/10.1016/S1470-2045(16)30030-4
